Only 2B3 and 2B12, but not control antibodies, inhibited the cleavage of sAPPa by b-sec-retase in a cell-free assay where the effects of antibody internalization and intracellular degrad
Trang 1Anti-amyloid precursor protein immunoglobulins inhibit amyloid-b production by steric hindrance
Rhian S Thomas1, J Eryl Liddell2and Emma J Kidd1
1 Welsh School of Pharmacy, Cardiff University, UK
2 Monoclonal Antibody Unit, School of Biosciences, Cardiff University, UK
Introduction
Alzheimer’s disease (AD) is characterized
pathologi-cally by an over-accumulation in the brain of
intracel-lular neurofibrillary tangles, amyloid-b (Ab)-containing
extracellular senile plaques and neuronal loss [1] The
‘amyloid hypothesis’ suggests that Ab accumulation in
the brain is an initiating event in AD [2], although it
does not explain all aspects of AD pathology [3]
Despite this, it is still the dominant theory used to explain the disease and many therapeutic strategies have therefore concentrated on attempting to modify
Ab accumulation in the brain [4]
Ab is a 38–43-mer peptide that is cleaved from amyloid precursor protein (APP) [5] APP can be processed by one of two proteolytic pathways The
Keywords
Alzheimer’s disease; amyloid precursor
protein; amyloid-b; monoclonal antibodies;
b-secretase cleavage site
Correspondence
E J Kidd, Welsh School of Pharmacy,
Cardiff University, Redwood Building, King
Edward VII Avenue, Cardiff CF10 3NB, UK
Fax: +44 29 20874149
Tel: +44 29 20875803
E-mail: KiddEJ@cf.ac.uk
Website: http://www.cardiff.ac.uk/phrmy/
contactsandpeople/fulltimeacademicstaff/
kidd-emmanew-overview_new.html
(Received 15 July 2010, revised 30
September 2010, accepted 27 October
2010)
doi:10.1111/j.1742-4658.2010.07942.x
The cleavage of amyloid precursor protein (APP) by b- and c-secretases results in the production of amyloid-b (Ab) in Alzheimer’s disease We raised two monoclonal antibodies, 2B3 and 2B12, that recognize the b-secretase cleavage site on APP but not Ab We hypothesized that these antibodies would reduce Ab levels via steric hindrance of b-secretase Both antibodies decreased extracellular Ab levels from astrocytoma cells, but 2B3 was more potent than 2B12 Levels of soluble sAPPa from the non-amyloidogenic a-secretase pathway and intracellular APP were not affected
by either antibody nor were there any effects on cell viability 2B3 exhib-ited a higher affinity for APP than 2B12 and its epitope appeared to span the cleavage site, whereas 2B12 bound slightly upstream Both of these factors probably contribute to its greater effect on Ab levels After 60 min incubation at pH 4.0, most 2B3 and 2B12 remained bound to their antigen, suggesting that the antibodies will remain bound to APP in the acidic endosomes where b-secretase cleavage probably occurs Only 2B3 and 2B12, but not control antibodies, inhibited the cleavage of sAPPa by b-sec-retase in a cell-free assay where the effects of antibody internalization and intracellular degradation were excluded 2B3 virtually abolished this cleavage In addition, levels of C-terminal APP fragments, generated following b-secretase cleavage (bCTF), were significantly reduced in cells after incubation with 2B3 These results strongly suggest that anti-cleavage site IgGs can generically reduce Ab levels via inhibition of b-secretase by steric hindrance and may provide a novel alternative therapy for Alzhei-mer’s disease
Abbreviations
Ab, amyloid-b; AD, Alzheimer’s disease; APP, amyloid precursor protein; BACE1, beta-site APP cleaving enzyme; bCTF, b-cleaved C-terminal APP fragments; CI, confidence interval; MTS, [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; PBS, phosphate-buffered saline; PBST, phosphate-buffered saline with 0.05% Tween 20.
Trang 2non-amyloidogenic route involves cleavage of APP by
a-secretase [6] within the Ab region to release sAPPa [7]
In the amyloidogenic pathway, b-secretase, identified as
beta-site APP cleaving enzyme (BACE1) [8–10], first
cleaves APP to liberate sAPPb and C99 [11] The
c-sec-retase complex [12–15] then cleaves C99 to produce Ab
and a C-terminal intracellular fragment [11] Although
there is still some debate regarding the co-localization of
the enzymes and substrates involved, it is generally
con-sidered that, after synthesis, a proportion of APP is
transported to the cell membrane and is then
internal-ized for processing in the endosomal–lysosomal system,
where it may be further processed to Ab [16,17]
Current therapy in the UK is limited to
symptom-atic treatment with acetyl-cholinesterase inhibitors for
moderate AD only [18] Recently, there has been much
attention given to the development of novel
immuno-therapeutic approaches in AD Ab vaccination, both
passive and active, has been used successfully in
trans-genic mice to reduce Ab plaque deposition [19] and
improve cognition [20–24] This led to a phase IIA
clinical trial involving vaccination with aggregated
Ab42, AN1792, but this was halted when several
patients developed meningoencephalitis [25]
Alterna-tive immunotherapeutic approaches are therefore
required
Here we present data relating to two monoclonal
antibodies, 2B12 and 2B3 Unlike the previous
approaches, our antibodies do not bind to Ab, but
bind to APP in the vicinity of the b-secretase cleavage
site We previously demonstrated that 2B12 reduced
levels of extracellular Ab40 from cell lines
endoge-nously expressing native APP in a time- and
concen-tration-dependent manner The mode of action was,
however, unclear [26] Here we present data
character-izing 2B3 and comparing the two antibodies We
dem-onstrate that 2B3 also reduces Ab levels from a native
cell line and is more potent than 2B12 This effect on
Ab levels was specific to the cleavage site antibodies
We suggest that these antibodies bind to the
extracellu-lar region of APP when it is transported to the cell
membrane and become internalized with the protein
into the endosomal⁄ lysosomal system where they
inhi-bit BACE1 cleavage via steric hindrance This will
drastically reduce levels of Ab produced, representing
an alternative therapeutic strategy to treat AD
Results
2B3 and 2B12 have different epitopes on APP
Both 2B3, an IgG1 isotype, and 2B12, an IgG2b
iso-type, detected full-length APP from MOG-G-UVW
cell lysates in a western blot (Fig 1) Both antibod-ies detected bands of 103 kDa (± 2.5 kDa) and
56 kDa (± 0.6 kDa) However, 2B3 recognized the
56 kDa fragment, possibly a thrombin cleavage frag-ment [27], more strongly than it did the 103 kDa fragment of APP, whereas 2B12 recognized the
103 kDa fragment more strongly than it did the
56 kDa fragment Neither antibody detected Ab40 in
an ELISA or western blot [26]; data not shown The antibodies differentially recognized sAPPa and sAPPb in an ELISA (Fig 1) There was no signifi-cant difference in the recognition by 2B12 of sAPPa
or sAPPb Similarly, there were no significant differ-ences in the amount of 2B3 bound to sAPPa when compared with the amount of 2B12 bound to either sAPPa or sAPPb However, significantly less 2B3 bound to sAPPb than sAPPa (P < 0.01) The amount of 2B3 bound to sAPPb was also signifi-cantly less than the binding of 2B12 to either sAPPa (P < 0.001) or sAPPb (P < 0.001)
103 kDa
A
B
56 kDa
0 2 4 6 8 10 12 14 16
2B3 2B12
***
Fig 1 (A) Representative western blot of MOG-G-UVW lysate (50 lg) detected with either 2B3 or 2B12 at 2 lgÆmL)1on a 10% gel Both antibodies detected full-length APP at 103 kDa (± 2.5 kDa) and a smaller protein at 56 kDa (± 0.6 kDa), probably a thrombin cleavage fragment of APP 2B3 preferentially recognized the 56 kDa fragment, n = 4–5 (B) Differential 2B3 and 2B12 recognition of sAPPa and sAPPb as determined by indirect ELISA Data are expressed as a mean (± standard error of the mean) percentage of the standard antibody (6E10) at 0.1 lgÆmL)1 2B12 recognized sAPPa and sAPPb equally well However, significantly more 2B3 bound to sAPPa than to sAPPb The amount of 2B3 bound to sAPPb was also significantly less than the amount of 2B12 bound
to either sAPPa or sAPPb **P < 0.01, ***P < 0.001 after one-way ANOVA and Bonferroni post-hoc tests, n = 4.
Trang 32B3 recognizes full-length APP and a peptide
spanning the cleavage site on APP more strongly
than 2B12
To determine the relative affinities of 2B3 and 2B12
for APP, we first compared their binding to a peptide,
Kb, which contains the b-secretase cleavage site on
APP (Fig 2) The antibodies differentially bound to
the peptide, as evidenced by their differential Hill
slopes, 0.90 for 2B3 and 0.63 for 2B12 (P < 0.001)
The antibody concentration at which half-maximal
binding was reached was significantly lower for 2B3,
1.279 lgÆmL)1 [95% confidence interval (CI) 1.153–
1.418], than for 2B12, 2.963 lgÆmL)1 (95% CI 1.696–
5.177) (P < 0.001) and the maxima reached for 2B3,
103.7% (95% CI 100.7–106.7) was significantly greater
than that for 2B12, 73.44% (95% CI 62.34–84.54)
(P < 0.001) Furthermore, significantly more 2B3 than
2B12 was detected bound to Kb at all antibody
con-centrations greater than 0.1 lgÆmL)1(P < 0.05)
We next compared their binding efficiency to
full-length APP in a competition ELISA using
MOG-G-UVW cell lysate as a source of APP Both 2B3 and
2B12 interfered with the binding of a commercial
detection antibody for APP in a
concentration-depen-dent manner (Fig 3) At 5, 10 and 20 lgÆmL)1, 2B12
significantly reduced the binding of the commercial
antibody to 90.5% (P < 0.01), 89.13% (P < 0.001)
and 82.9% (P < 0.01) of control levels, respectively
This was similar to previously reported levels [26] At
5, 10 and 20 lgÆmL)1, 2B3 also significantly reduced the binding of the second commercial antibody to
87.4% (P < 0.01), 82.33% (P < 0.001) and 72.94% (P < 0.001) of control levels Even at the highest con-centration, 20 lgÆmL)1, a control IgG did not signifi-cantly reduce the binding of the second detection antibody when compared with control levels The three antibodies differentially inhibited the binding of the APP detection antibody at 1 lgÆmL)1 (P < 0.05),
5 lgÆmL)1 (P < 0.001), 10 lgÆmL)1 (P < 0.001) and
20 lgÆmL)1 (P < 0.001) 2B3 and 2B12 produced a significantly greater inhibition in the binding of the APP detection antibody than did the control IgG at all concentrations tested (P < 0.05) At 10 lgÆmL)1 (P < 0.01) and 20 lgÆmL)1(P < 0.001), 2B3 also sig-nificantly inhibited binding of the detection antibody more than 2B12
The majority of both 2B3 and 2B12 remained bound to their antigen, Kb, after incubation at different pH values
To determine the effects of pH on the antibodies, 2B3 and 2B12 were bound to the Kb peptide at pH 7.4 and then incubated for 0 or 60 min at pH 4.0 or 7.4 There
0
20
40
60
80
100
120
2B3
2B12
*
*
*
*
*
*
*
*
Fig 2 Half-maximal binding of 2B3 and 2B12 to a peptide, Kb,
spanning the b-secretase cleavage site, as determined by ELISA.
Data are expressed as a mean (± standard error of the mean)
per-centage of the standard antibody (6E10) at 0.05 lgÆmL)1 The
con-centration at which half-maximal binding was reached was
significantly lower for 2B3 than for 2B12 (P < 0.001) *Significant
differences between 2B3 and 2B12 with two-tailed Student’s
t-tests, P < 0.05, n = 3–4.
70 75 80 85 90 95 100 105
2B3 2B12 Control IgG
a
a b
b
***
***
** b
** b
b
***c
Fig 3 Binding of 2B3, 2B12 or a control IgG to APP as determined
by a competition sandwich ELISA for APP Data are expressed as mean (± standard error of the mean) percentage of the media con-trol One-way ANOVA indicated that the antibodies differentially inhibited the binding of a commercial anti-APP IgG at each antibody concentration Antibody data points followed by different letters (either a, b or c) differ significantly from each other in their ability to inhibit the commercial antibody at that particular antibody concen-tration after one-way ANOVA and Bonferroni (P < 0.05) 2B3 and 2B12 also significantly reduced the binding of the commercial anti-body in comparison with media controls at 100% **P < 0.01,
***P < 0.001, significantly different from media controls using two-tailed Student’s t-tests The control IgG did not significantly inter-fere with the binding of the detection antibody, n = 4.
Trang 4were significant differences between the persistence in
binding of the antibodies to Kb under the various
con-ditions tested (P < 0.001) (Fig 4) There was also a
significant interaction between the antibody type (2B3
or 2B12) and pH (P < 0.05) The complex formed
between 2B12 and Kb was not significantly affected by
pH or incubation time The complex formed between
2B3 and Kb was also not significantly affected by the
incubation period, but there was a significant reduction
in 2B3 binding at pH 4.0 after 60 min (P < 0.05)
Incubation of Kb with phosphate-buffered saline with
0.05% Tween 20 (PBST) alone at pH 4.0 for 1 h, prior
to incubation with antibody at pH 7.4, did not affect
the binding of either 2B3 or 2B12 (data not shown),
indicating that the above results are not due to
degra-dation of the antigen Importantly, even at pH 4.0,
there was still significantly more 2B3 bound to Kb
than 2B12
2B3 is more effective at reducing extracellular
Ab40 and Ab42 levels in cell culture media than
2B12
The antibodies tested differentially inhibited levels of
extracellular Ab40 (P < 0.001) (Fig 5A) 2B12
signifi-cantly reduced levels of Ab40 in MOG-G-UVW cell
media to 65.3% of media control levels (P < 0.05) This was similar to levels previously reported [26] 2B3 significantly reduced levels of extracellular Ab40 to 36.8% of media control levels (P < 0.001) Neither the control IgG nor the anti-N-terminal APP IgG had any significant effect on Ab40 levels Both 2B3 and 2B12 significantly reduced Ab40 more than the anti-N-terminal APP IgG (P < 0.001, P < 0.05, respec-tively) and 2B3 significantly reduced Ab40 levels more than 2B12 (P < 0.05)
The antibodies also differentially inhibited levels of Ab42 (P < 0.05) 2B12 significantly reduced Ab42 lev-els to 54.8% of the media control (P < 0.01) 2B3 was again more effective and reduced these levels to 21.9%
of media control levels (P < 0.01) (Fig 5B) Ab42 levels
0
10
20
30
40
50
60
70
80
90
100
2B3 2B12
*** ***
*
*
Fig 4 Effect of pH and incubation time on persistence of 2B3 and
2B12 binding to Kb as determined by ELISA Data are expressed
as mean (± standard error of the mean) percentage absorbance of
the standard antibody, 6E10 (0.05 lgÆmL)1) Antibodies were first
allowed to form a complex with Kb at pH 7.4 and the complex was
then incubated with buffers of pH 4.0 or 7.4 for 0 and 60 min The
complex formed between Kb and 2B3 was not affected by
incuba-tion time, but was significantly affected by the pH of the buffer.
The persistence in binding of 2B12 to Kb was not significantly
affected by either incubation time or pH At all values tested,
signif-icantly more 2B3 remained bound to the Kb peptide than 2B12.
*P < 0.05, ***P < 0.001, 2B3 significantly different to 2B12 Data
were analysed for statistical significance with Generalized Linear
Model univariate analysis and Bonferroni post-hoc tests, n = 3–4.
0 20 40 60 80 100 120
140
A
B
β40 (% of control) ***
**
a
b
0 20 40 60 80 100 120 140
β42 (% of control) **
**
c
Fig 5 Levels of extracellular Ab40 (A) and Ab42 (B) from MOG-G-UVW culture media after incubation with 2B3, 2B12, an irrelevant mouse IgG (Ab40 only) or an anti-N-terminal APP IgG (N), all at
10 lgÆmL)1for 48 h Data are expressed as mean (± standard error
of the mean) percentage of media control Ab levels as detected in
a sandwich ELISA and corrected for total cell protein concentration Both 2B3 and 2B12 significantly reduced both forms of Ab from media controls Neither of the control antibodies had any significant effect on Ab levels *P < 0.05, **P < 0.01, ***P < 0.001, signifi-cantly different from media controls (100%) with two-tailed Student’s t-tests a P < 0.05, significantly different from all other groups; b P < 0.05 significantly different from 2B3 and N; c P < 0.05 significantly different from N after ANOVA and Tukey’s Honestly Significant Difference, n = 3–6 (A) and n = 4 (B).
Trang 5remained at 100.1% of control levels after incubation
with the anti-N-terminal APP IgG Again, 2B3
signifi-cantly reduced Ab42 levels more than the
anti-N-ter-minal IgG (P < 0.05)
Anti-b-secretase cleavage site IgGs do not alter
levels of APP, sAPPa, or affect cell viability, but
reduce b-cleaved C-terminal APP fragment (bCTF)
levels
Neither 2B12, 2B3 nor the irrelevant IgG had any effect
on levels of intracellular APP as measured in an ELISA
(Fig 6A) Furthermore, they did not have any
signifi-cant effect on the number of viable cells, as measured
using an MTS assay with
[3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetra-zolium, inner salt (Fig 6B) The anti-N-terminal APP
IgG appeared to either increase the number of cells or
alter the levels of metabolic activity above control levels (P < 0.01) Neither 2B12 nor the control IgG had any significant effect on the levels of sAPPa (Fig 7A) However, incubation with 2B3 significantly reduced bCTF levels to 64.6% (P < 0.05) of control values in MOG-G-UVW cells (Fig 7B)
Anti-b-secretase cleavage site IgGs reduce BACE1 cleavage via steric hindrance in a cell-free assay Neither 2B3, 2B12, the control IgG nor the anti-N-ter-minal APP IgG had any detectable effects on total lev-els of BACE1 in MOG-G-UVW cells, as investigated
by western blotting (data not shown) However, differ-ences were observed in BACE1 activity after in vitro incubation of sAPPa with BACE1 and the antibodies The antibodies tested differentially inhibited the cleav-age of sAPPa by BACE1, as detected by western blot-ting (P < 0.001) (Fig 8A,B) There was a decrease in
0
20
40
60
80
100
120
A
B
0
20
40
60
80
100
120
140
160
180
200
**
Fig 6 Levels of intracellular APP as determined by ELISA (A) and
cell viability as determined by MTS assay (B) in MOG-G-UVW cells
after incubation with 2B3, 2B12, an anti-N-terminal APP IgG (N,
MTS only) or a control irrelevant mouse IgG, all at 10 lgÆmL)1for
48 h Data are expressed as mean (± standard error of the mean)
percentage of control (media only) APP levels were corrected for
total cell protein concentration None of the antibodies tested had
any significant effect on levels of APP or cell viability, apart from the
anti-N-terminal APP IgG, which appeared to stimulate growth.
**P < 0.01, significantly different from media control using
two-tailed Student’s t-tests, n = 3.
0 20 40 60 80 100 120 140 160 180 200
A
B
0 20 40 60 80 100 120
*
Fig 7 Levels of extracellular sAPPa (A) and intracellular bCTF (B)
as determined by ELISA from MOG-G-UVW cells after incubation with 2B12, 2B3 or a control irrelevant mouse IgG, all at 10 lgÆmL)1 for 48 h Data are expressed as mean (± standard error of the mean) percentage of control (media only) All levels were corrected for total cell protein concentration Neither 2B12 nor the IgG anti-body significantly affected levels of sAPPa However, 2B3 signifi-cantly reduced levels of bCTF from control levels *P < 0.05, significantly different from media controls using two-tailed Student’s t-tests, n = 3.
Trang 6sAPPa levels from control levels (sAPPa alone) after
incubation with BACE1 (media control) of )41.91 A
units Neither the control IgG nor the anti-N-terminal
APP IgG had any significant effect on the activity of
BACE1 and decreases in sAPPa on the addition of
BACE1 were similar to those observed in the presence
of control media alone (–)6.9 and )44.4 A units,
respectively) The addition of both 2B3 and 2B12
sig-nificantly inhibited the action of BACE1 from control
conditions 2B12 significantly reduced this decrease in
sAPPa levels to only )17.29 A units (P < 0.05) 2B3
virtually abolished the reduction in sAPPa caused by
BACE1 and the decrease in sAPPa levels was only
)0.05 A units (P < 0.01) Levels of sAPPa were very
similar to the levels observed when sAPPa was
incu-bated with 2B3 alone
Discussion
Both 2B3 and 2B12 were raised to the same
immuno-gen, yet they clearly have different epitopes, as
evi-denced by their binding profile to APP in western
blotting and by their differential binding to sAPPa
and sAPPb 2B3 binds significantly less to sAPPb than
it does to sAPPa (25% less), whereas 2B12 recog-nizes sAPPb and sAPPa equally well The evidence suggests that 2B12 binds upstream of the b-secretase cleavage site (towards the N-terminal of APP), as it recognizes both sAPPa and sAPPb Its epitope, there-fore, is in a region common to both peptides Although 2B3 also recognizes both of these APP frag-ments, more 2B3 bound to sAPPa than to sAPPb However, 2B3 does not recognize the Ab peptide This suggests that 2B3 binds across the b-secretase cleavage site, and only slightly into the Ab region (Fig 9) Results from a BLAST (http://www.ncbi.nlm.nih gov) search on the Ka peptide used to raise both anti-bodies indicated that they should be specific to APP as this sequence of amino acids is highly conserved in APP and not found in other mammalian sequences (data not shown) In addition, we have previously demonstrated that there was no cross-reaction between 2B12 and a range of peptides tested by ELISA or wes-tern blotting [26]
2B3 binds more effectively to APP than 2B12, as demonstrated by a competition assay, in which 2B3 interfered with the binding of a second detection anti-body for APP more efficiently than 2B12 Although these results could be due to the differential epitopes
or isotypes of 2B3 and 2B12, meaning that 2B3 might interfere more effectively with the binding of the APP detection antibody, they do suggest that 2B3 has a higher relative affinity for APP than 2B12 This is sup-ported by the results of the affinity rankings of the two antibodies for the Kb peptide, a 15-mer frag-ment spanning the b-secretase cleavage site on APP Significantly more 2B3 than 2B12 bound to Kb at all
sAPPα and BACE1 incubated with
:-–60
–50
–40
–30
–20
–10
0
Media control
**
*
A
B
Fig 8 (A) Representative western blot of sAPPa incubated with or
without BACE1 and 2B12, 2B3, control IgG, anti-N terminal APP
IgG (N) (all at 1 lgÆmL)1) or media control Lane 1, sAPPa alone;
lane 2, sAPPa and BACE1 (media control); lane 3, sAPPa and
2B12; lane 4, sAPPa, BACE1 and 2B12; lane 5, sAPPa and 2B3;
lane 6, sAPPa, BACE1 and 2B3; lane 7, sAPPa and IgG; lane 8,
sAPPa, BACE1 and IgG; lane 9, sAPPa and N; lane 10, sAPPa,
BACE1 and N Only 2B12 and 2B3 inhibited the action of BACE1 in
this system (B) Quantification of western blots showing the mean
(± standard error of the mean) change in sAPPa from relevant
con-trol levels (i.e sAPPa and relevant antibody alone) after sAPPa
incubation with BACE1 and either 2B3, 2B12, control IgG, anti-N
terminal APP IgG (N) or media alone *P < 0.05, significantly
differ-ent from media control and N; **P < 0.01 significantly differdiffer-ent
from media control, IgG and N, after one-way ANOVA and
Bonfer-roni post-hoc tests, n = 3–6.
αα-secretase cleavage site 2B3
Aβ COOH
NH 2
2B12
β-secretase cleavage site sAPPβ
sAPPα
APP
Fig 9 Hypothesized epitopes of 2B3 and 2B12 on APP 2B3 binds across the b-secretase cleavage site, whereas 2B12 binds upstream of this Neither antibody recognizes Ab when cleaved from APP.
Trang 7concentrations greater than 0.1 lgÆmL)1 and the
con-centration for half-maximal binding was significantly
lower for 2B3 All these data suggest that 2B3 has a
higher relative affinity for APP than 2B12
We hypothesize that 2B3 and 2B12 will bind to the
APP ectodomain after APP has trafficked to the cell
membrane and will be endocytosed into the cell with the
protein Indeed, Tampellini et al [28] demonstrated that
antibodies to the N- and mid-region of Ab bound first
to the ectodomain of APP and were then internalized
This immunocomplex would be formed at ‘normal
phys-iological pH’, presumably around pH 7.4 Once
inter-nalized, however, the complex may enter organelles,
where it would be subjected to much lower pH values,
potentially as low as pH 4.5 [29,30] Low pH is well
known to affect antibody binding [31] Therefore, we
tested the persistence of the immunocomplex, after it
had formed at pH 7.4, at two different pH values The
persistence of the immunocomplex formed when 2B12
bound to Kb was not significantly affected by pH or
incubation time Similarly, the Kb⁄ 2B3
immunocom-plex was not affected by incubation time, but a decrease
in pH did significantly reduce its persistence
Neverthe-less, significantly more 2B3 than 2B12 remained bound
to the Kb peptide at all pH values and time points
tested, and 2B3 also retained nearly 70% of its original
binding capacity We therefore suggest that both
anti-bodies would retain a large proportion of their
biologi-cal activity, even under the low pH conditions found in
the endosomal⁄ lysosomal system [29,30] Furthermore,
the lack of an effect of time suggests that the
immuno-complexes formed will persist for a biologically relevant
period of time
Having demonstrated that 2B3 bound more
effi-ciently to APP than 2B12, we then investigated
whether it reduced the production of Ab40 in a similar
manner to 2B12 Both 2B3 and 2B12 significantly
reduced extracellular levels of Ab40 However, neither
the anti-N-terminal APP IgG nor the control mouse
IgG had any effect on Ab40 This suggests that it is
not sufficient to have an antibody that binds to APP
in order to reduce Ab, but that the antibodies must
bind in the vicinity of the b-secretase cleavage site to
accomplish this effect We also investigated whether
either antibody affected the more aggregatory species
of Ab, Ab42, as there have been suggestions that the
majority of this peptide is cleaved from APP within
the trans-golgi network or the endoplasmic reticulum,
prior to the trafficking of APP to the cell membrane
[32] If this were indeed the case, then our
anti-cleav-age site IgGs might be ineffective against this species
of Ab Again, both 2B3 and 2B12 significantly reduced
Ab42 from control levels, but the N-terminal antibody
had no effect This would suggest that at least a por-tion of this peptide is produced elsewhere in the cell rather than in the secretory pathway, and after APP translocation to the cell membrane It is interesting to note that, in both cases, 2B3 reduced levels of Ab40 and Ab42 more than 2B12, although this was only sig-nificant in the case of Ab40 This could be because of the higher relative affinity of 2B3 for APP over 2B12 Alternatively, it could be a function of its epitope, as
by binding closer to the cleavage site than 2B12, it may block the access of BACE1 to APP via steric hin-drance more effectively than 2B12 Clearly, informa-tion regarding the mode of acinforma-tion of the antibodies is important
There are three predominant theories that have been used to explain how Ab-specific antibodies may bring about the clearance of Ab [33]: disruption of Ab aggre-gates or neutralization of Ab oligomers, Fc-receptor-mediated phagocytosis of Ab by microglia and the peripheral sink hypothesis, in which the sequestration
of circulating Ab causes an efflux of Ab from the brain
to the plasma [34,35] 2B3 and 2B12 are unlikely to exert their effects by any of these mechanisms, as nei-ther binds to Ab We previously demonstrated that 2B12 was not toxic to cells in culture [26] and neither the cleavage site antibodies nor the control IgG anti-body affected cell viability levels here The cleavage site antibodies are therefore not reducing levels of Ab
by initiating cell death In contrast, the anti-N-terminal APP IgG led to increased absorbance levels in the MTS assay However, we did not explore this finding any further because we had already demonstrated that this commercially available antibody did not affect Ab levels and therefore was likely to behave in a very dif-ferent manner to the cleavage site antibodies Further-more, 2B12 did not alter detectable cleavage by the non-amyloidogenic pathway in MOG-G-UVW cells, as sAPPa levels remained unchanged
It has been demonstrated that anti-N-terminal Ab Igs, which can reduce Ab pathology in vivo, can reduce intracellular levels of Ab in vitro only when internalized into cells [28], yet none of the theories described above fully explain how intracellular Ab lev-els may be reduced We have demonstrated that 2B3 and 2B12 can reduce levels of extracellular Ab It is therefore probable that our antibodies are also reduc-ing levels of intracellular Ab This is particularly likely
as neither of the antibodies bind to the Ab peptide itself and cannot therefore be increasing its extracellu-lar degradation, or interfering with the assay We were, however, unable to measure intracellular Ab40
or Ab42 because of the low levels detectable in our native cell lines
Trang 8Internalized anti-Ab Igs or anti-cleavage site IgGs
may inhibit the action of b-secretase However,
Tam-pellini et al [28] saw no evidence of this with anti-Ab
Igs Tampellini et al [28] observed that Ab and APP
ectodomain antibodies induced increased APP
internal-ization from the cell surface, which actually led to
enhanced cleavage by b-secretase and subsequently to
enhanced clearance of the antibody-bound bCTF
frag-ments in the lysosomal system 2B3 and 2B12 did not
alter intracellular APP levels Therefore, it seems
unli-kely that their mode of action is via increased
degrada-tion of APP Unlike Tampellini et al [28], we observed
a significant decrease in bCTF levels after incubation
with 2B3 This would imply that the cleavage site
anti-bodies do not induce increased internalization of APP
leading to enhanced cleavage by b-secretase, but that
they are reducing Ab by a different mechanism It
sug-gests that they are inhibiting the cleavage of APP by
b-secretase The lack of a significant effect after
incu-bation with 2B12 may be a result of the smaller effect
that this antibody has on Ab levels
We hypothesized that 2B3 and 2B12 were blocking
the action of b-secretase by steric hindrance We
there-fore devised a simple cell-free system to investigate this
hypothesis that avoided complications from other
cellular components and overcame the low levels of
APP fragments in the native cell lines Both 2B3 and
2B12 drastically reduced or nearly abolished BACE1
cleavage of sAPPa This clearly demonstrates that
anti-cleavage site IgGs are capable of inhibiting
BACE1 in vitro The presence of a large protein (IgG)
did not nonspecifically block the action of BACE1
Crucially, our results demonstrate that antibody
epi-topes are vitally important to this inhibition, as the
anti-N-terminal APP IgG, which binds some distance
from the cleavage site, had no such effect on BACE1
In this simple in vitro system, any effects of APP
inter-nalization or enzyme⁄ substrate co-localization are
eliminated In conjunction with the observed decrease
in bCTF levels, results from the cell-free assay system
suggest that the mode of action of our cleavage site
antibodies is probably via steric hindrance
Similar effects on Ab levels were obtained by Arbel
et al [36], who produced monoclonal antibodies using
a peptide containing part of the Swedish mutation at
the b-secretase cleavage site They also demonstrated a
reduction in both extracellular and intracellular Ab
levels, but in cell lines over-expressing APP These
antibodies have also been shown to improve cognition
in the Tg2576 Swedish mutation mouse model of AD
pathology [37] and to reduce Ab levels in the V717I
London mutation mouse model [38] We believe that
our use of model cell lines that do not over-express
APP is very important, as the majority of cases of AD occur in people with much lower levels of APP than those associated with transfected cells As far as we are aware, we have demonstrated for the first time that the most likely mode of action for such antibodies is via steric hindrance
Immunotherapy for AD remains an exciting pros-pect, despite the failure of the AN1792 clinical trial [39] Passive immunization with b-secretase cleavage site antibodies might alleviate some of the problems associated with this trial, such as the T-lymphocyte meningoencephalitis and cerebral micro-haemorrhages [40,41] These antibodies would not bind to existing
Ab and would not therefore stimulate the T-lympho-cyte response or lead to the excessive complement activation that some believe would be a problem with
Ab antibodies [42] In conjunction with other immuno-therapeutic strategies to reduce plaque load, such anti-bodies may have a considerable impact on the development of disease-modifying treatments for AD
Materials and Methods
Materials and cell culture
All chemicals and reagents were purchased from Sigma-Aldrich (Poole, UK) or Fisher Scientific (Leicester, UK) and all reactions were performed at room temperature unless otherwise specified
Astrocytoma cells, MOG-G-UVW (ECACC, Porton Down, UK), were cultured in a 1 : 1 mix of Ham’s F10 and Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum (Perbio Science UK Ltd, Cramlington, UK) and 2 mm l-glutamine
Antibody production and isotyping
Full details of the immunization protocol and hybridoma development are detailed elsewhere [26] Antibodies (2B12 and 2B3) were raised to a 15-mer peptide spanning the b-secretase cleavage site on APP, EEISEVKMDAEFRHD, termed Ka Both antibodies were concentrated from culture medium using Amicon Centriplus YM-100 filters (Millipore, Watford, UK) with a nominal molecular mass cut-off of 100 kDa and the isotype determined using the Isostrip mouse monoclonal antibody isotyping kit (Serotec, Oxford, UK)
Western blotting was performed using standard meth-ods Briefly, samples were resolved on 10% polyacrylamide gels, transferred on to 0.2 lm nitrocellulose membranes (Amersham Biosciences, Little Chalfont, UK), incubated with the relevant antibody and detected as previously described [26]
Trang 9Determination of antibody epitopes
The epitopes of 2B3 and 2B12 on APP were investigated
by western blotting, as above, and by comparing the
relative binding profiles of the antibodies with cleavage
products of APP in an indirect ELISA Recombinant
sAPPa and sAPPb (Sigma-Aldrich) were adsorbed to a
96-well microtitre plate (Greiner Bio-One, Stonehouse,
UK) at 5 lgÆmL)1in carbonate⁄ bicarbonate buffer (15 mm
Na2CO3, 35 mm NaHCO3, pH 9.8) overnight at 4C
Plates were blocked with 1% nonfat milk powder for 1 h,
then 2B3 or 2B12 was subsequently incubated at 1 lgÆmL)1
for 2 h Antibodies were detected with a secondary
anti-mouse IgG conjugated to horseradish peroxidase, 1 : 2500
(Pierce, Rockford, IL, USA) for 1 h and visualized with
the enzyme substrate, o-phenylenediamine in a 0.1 m citrate
phosphate buffer (24 mm citric acid, 51 mm Na2HPO4, pH
5.0), incubated for 20 min The reaction was stopped with
2.5 m H2SO4 and the absorbance determined at 492 nm
The diluent used on day 2 was phosphate-buffered saline
(PBS; 137 mm NaCl, 1.5 mm KH2PO4, 8 mm Na2HPO4,
2.5 mm KCl, pH 7.4) with 0.05% Tween 20 (PBST) All
results were expressed as a proportion of the standard
anti-body (6E10, Cambridge BioScience Ltd, Cambridge, UK)
at 0.1 lgÆmL)1 bound to sAPPa, to correct for any
inter-plate variation
Quantification of APP
APP was quantified using the APP DuoSet (R&D Systems,
Abingdon, UK) following the manufacturer’s guidelines
[26] Briefly, the capture antibody was used at 4 lgÆmL)1in
PBS overnight Plates were blocked with 1% bovine serum
albumin and 5% sucrose in PBS and samples were
quanti-fied using a six-point standard curve The biotinylated
detection antibody was used at 300 ngÆmL)1 and detected
using streptavidin–horseradish peroxidase and
o-phenylene-diamine
Affinity ranking of 2B3 and 2B12 for an APP
fragment
Affinity ranking of the two antibodies was accomplished by
comparing their binding properties to a peptide, Kb, which
spans the b-secretase cleavage site on APP, in an indirect
ELISA This peptide represents a 15-mer sequence
(SEV-KMDAEFRHDSGY), slightly further into the Ab region
of APP than Ka, the immunizing peptide ELISA methods
followed those detailed above with the following exceptions
Kb was adsorbed to a 96-well microtitre plate at a
concen-tration of 10 lgÆmL)1 in carbonate⁄ bicarbonate buffer
overnight at 4C 2B3 or 2B12 was incubated for 2 h at
concentrations ranging from 0.00001 to 30 lgÆmL)1 and
detected as above All results were expressed as a
propor-tion of the standard antibody (6E10) at 0.05 lgÆmL)1
Binding of 2B3 and 2B12 to full-length APP
A competition assay, in conjunction with the sandwich ELISA for APP (R&D Systems) described above, was used
to determine relative binding of 2B3 and 2B12 to APP from cell lysates MOG-G-UVW cells were lysed and concen-trated through a filter with a nominal cut-off of 100 kDa (Millipore) to provide predominantly full-length APP at a concentration of 30 ngÆmL)1, as described previously [26] After formation of the APP⁄ capture antibody complex on the 96-well plate and prior to incubation with the detection antibody, the test antibodies, 2B3, 2B12 or control IgG (Pierce), were incubated at concentrations ranging from 1
to 20 lgÆmL)1for 1 h Binding of these antibodies was then inferred by a decrease in binding of the detection antibody compared with the PBST control alone
Persistence of 2B3 and 2B12 binding at different
pH values
The binding persistence of 2B3 and 2B12 to Kb was investi-gated at two different pH values using an indirect ELISA The methods followed those detailed above with the follow-ing modifications Kb was adsorbed to a 96-well plate and blocked as above 2B3 and 2B12 (5 lgÆmL)1) were incubated with Kb for 1 h in PBST (pH 7.4) and the antibody solution was aspirated The immunocomplex was then incubated for
a further 1 h in PBST at either pH 7.4 or 4.0 for 0 or
60 min To ensure that the antigen was not degraded or dis-sociated from the plate by the pH treatment, Kb was also incubated with PBST alone at pH 4.0 for 1 h prior to incu-bation with 2B3 or 2B12 at pH 7.4 Binding of both antibod-ies was detected as above and all results were expressed as a proportion of a standard antibody (6E10) at 0.05 lgÆmL)1 PBST was adjusted to the correct pH with H3PO4
Effects of 2B3 and 2B12 on levels of Ab40, Ab42, sAPPa and bCTF
All experiments were performed in 24-well cluster plates, in triplicate, with a starting density of 25 000 MOG-G-UVW cells per well Cells were allowed to attach overnight and were then incubated with control media, 2B3, 2B12, an anti-N-terminal APP IgG (22C11, Millipore) or an
10 lgÆmL)1) for 48 h at 37C This was repeated on a min-imum of three different passage numbers, where each
n= 1 passage For analysis of Ab40, media was subjected
to immunoprecipitation and ELISA as described previously [26] Briefly, the ELISA employed the N-terminal Ab anti-body 6E10 (5 lgÆmL)1) as the capture antibody and affin-ity-purified BAM401AP (0.45 lgÆmL)1 Autogen Bioclear, Calne, UK), specific to the C-terminus of human Ab40, as the detection antibody For analysis of Ab42, media was collected after antibody treatment and tested in a sandwich
Trang 10ELISA (Biosource, Invitrogen, Paisley, UK) To determine
the effect of the antibodies on sAPPa, MOG-G-UVW cells
were incubated as before and media was tested in a
sand-wich ELISA (IBL, Hamburg, Germany) All cells were
lysed and intracellular APP and bCTF (IBL) levels were
detected by ELISA, as described above All data were
nor-malized to total cell protein concentration as determined by
bicinchoninic acid protein assay (Pierce)
Effect of 2B3 and 2B12 on MOG-G-UVW cell
viability
Viability studies were performed on MOG-G-UVW cells
after incubation with 2B3, 2B12, control IgG
(Sigma-Aldrich), anti-N-terminal APP IgG (22C11, Millipore) or
media control, all at 10 lgÆmL)1, using the CellTiter 96
MTS Aqueous One Solution Cell Proliferation Assay
(Pro-mega, Southampton, UK) in 96-well cluster plates
MOG-G-UVW cells were first allowed to adhere overnight after
plating at a concentration of 2000 per well, and were then
incubated with treatments for 48 h Viability was assessed
following the manufacturer’s guidelines
Effect of 2B3 and 2B12 on BACE1 activity in a
cell-free assay
The effect of 2B3 and 2B12 on BACE1 levels was
investi-gated, after antibody treatment as detailed above, and
analy-sed by western blotting 12.5 g total protein was run on the
polyacrylamide gel and detected with anti-BACE1 IgG
(0.27 lgÆmL)1, Santa Cruz Biotechnology, Santa Cruz,
USA) The effect of the antibodies on BACE1 activity was
also investigated in a cell-free assay Recombinant human
sAPPa (4 lgÆmL)1, R&D Systems), containing the
b-secre-tase cleavage site, was incubated in the presence or absence
of BACE1 (82.5 lgÆmL)1, R&D Systems) for 1 h at 37C,
with the addition of one of the following treatments, 2B3,
2B12, control IgG (Pierce), anti-N-terminal APP IgG or
media control Prior to the addition of BACE1, the
antibod-ies and sAPPa were allowed to form a complex for 3 min
The total reaction volume was 20 lL; all reactions were
per-formed in 50 mm C2H3O2Na (pH 4.5) and all antibodies
were used at 1 lgÆmL)1 The reaction was stopped by the
addition of 3· Laemmli sample buffer [43] A volume
equiv-alent to 26.67 ng starting sAPPa was analysed in a western
blot and detected with the anti-N-terminal APP IgG
(33.3 ngÆmL)1)
Statistical analyses
Data generated in ELISA assays were quantified by
com-paring data with standard curves included on each plate,
using graphpad prism4 The results were first normalized
to total protein concentration, where relevant, and
expressed as a percentage of media control values MTS and ELISA results were then analysed using a Student’s t-test at the two-tailed significance level to determine if con-centrations were significantly different to media controls (100%) Where relevant, ELISA data were subsequently analysed with one-way ANOVA
To compare the relative affinities of 2B3 and 2B12 for the Kb peptide, log antibody concentration was plotted against the percentage absorbance (of standard antibody) and a sigmoidal dose–response curve fitted to the data using graphpad prism 4 Curve parameters were com-pared using the F-test and differences between 2B3 and 2B12 at each concentration were compared using a Stu-dent’s t-test The persistence in binding of 2B3 and 2B12 to
Kb at different pH values was investigated using General-ized Linear Model univariate analysis, with absorbance as the dependent variable and pH, antibody and time as fac-tors Both antibodies were subsequently investigated inde-pendently with ANOVA and Bonferroni
Western blots for the inhibitory effects of 2B3 and 2B12
on BACE1 were quantified using nih imager All bands were first normalized to, and expressed as a percentage of, sAPPa alone, to allow comparisons between blots The normalized control density of sAPPa and antibody was subtracted from the relevant experimental condition of sAPPa, antibody and BACE1 to determine the change in sAPPa after incubation with BACE1 The resulting change in sAPPa was analysed using one-way ANOVA and Bonferroni
Where necessary, data were transformed to fulfil the assumptions of normality and homoskedasticity and, there-fore, to allow the use of parametric testing
Acknowledgements
This work was funded by grant number 79 from the Alzheimer’s Society, UK We would like to thank Katrin Hack, Pavlina Doubkova, Lynne Murphy and Shahista Jaffer for their technical assistance with this project
References
1 Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy Physiol Rev 81, 741–766
2 Hardy J & Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer’s disease Trends Pharmacol Sci 12, 383–388
3 Bennett DA, Schneider JA, Wilson RS, Bienias JL & Arnold SE (2004) Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function Arch Neurol 61, 378–384
4 Hamaguchi T, Ono K & Yamada M (2006) Anti-amyloidogenic therapies: strategies for prevention and